Hyperliquid Strategies Inc (PURR) Stock Price, Quote & News

Company Profile

Hyperliquid Strategies Inc., through its subsidiary, operates as a a biotechnology company that owns a platform for biologic medicines of single or bifunctional action. The company was incorporated in 2025 and is based in New York, New York.

Industry: Capital Markets

Sector: Financial Services

Address:

477 Madison Avenue, New York, United States

nerowinger Feb. 3 at 8:30 PM

$PURR i dont no whats better holding purr or hype coin??

0 · Reply

nerowinger Feb. 3 at 7:23 PM

$PURR added

0 · Reply

Concreteslinger Feb. 3 at 6:58 PM

$PURR when options?!?

0 · Reply

insanitywolftrading Feb. 3 at 2:34 PM

$PURR son of a bitch

0 · Reply

insanitywolftrading Feb. 3 at 2:02 PM

$PURR need this shit to double so daddy can get a vasectomy!!!

0 · Reply

insanitywolftrading Feb. 3 at 12:48 PM

$PURR $HYPE.X look at this moist fellow who thinks now is a good time to bet against HYPEmentum season. It’s going up little fella, I just thought it would go up more. It’s getting there

0 · Reply

insanitywolftrading Feb. 3 at 12:36 PM

$HYPE.X huh I thought $PURR would be up given this huge move

1 · Reply

insanitywolftrading Feb. 3 at 4:01 AM

$HYPE.X $PURR is gonna go nuts tomorrow

0 · Reply

cheating_stock_investor Feb. 3 at 2:49 AM

$HYPD $HYPE.X $PURR $HYPE.X should break ath the first q of this year. Until x payments gets their payment platform up this should replace $DOGE.X in the top 10

0 · Reply

insanitywolftrading Feb. 3 at 1:58 AM

$HYPD $HYPE.X $PURR these are all gonna rip tomorrow we caught a big move

0 · Reply

Hyperliquid Strategies Inc Announces $30 million Stock Repurchase Program

Dec 3, 2025, 5:45 PM EST - 2 months ago

Ex-Barclays CEO unpacks Hyperliquid: ‘The FUTURE of finance'

Dec 2, 2025, 4:30 PM EST - 2 months ago

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Nov 18, 2025, 9:00 AM EST - 2 months ago

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

Oct 15, 2025, 10:03 AM EDT - 3 months ago

Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma

Sep 19, 2025, 9:00 AM EDT - 4 months ago

Sonnet to Present at the MedInvest Biotech & Pharma Conference

Aug 11, 2025, 9:15 AM EDT - 6 months ago

Sonnet Releases Virtual Investor "What This Means" Segment

Aug 4, 2025, 8:40 AM EDT - 6 months ago

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Jul 14, 2025, 11:30 AM EDT - 7 months ago

Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?

Jul 14, 2025, 6:00 AM EDT - 7 months ago

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

May 1, 2025, 9:00 AM EDT - 9 months ago

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Apr 4, 2025, 9:00 AM EDT - 10 months ago

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Apr 1, 2025, 4:15 PM EDT - 11 months ago

Sonnet Announces Release of Corporate Update Video

Apr 1, 2025, 7:30 AM EDT - 11 months ago

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Mar 26, 2025, 9:05 AM EDT - 11 months ago

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Mar 19, 2025, 8:50 AM EDT - 11 months ago

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Mar 11, 2025, 8:45 AM EDT - 11 months ago

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 26, 2025, 9:00 AM EST - 1 year ago

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Feb 19, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Feb 18, 2025, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Feb 13, 2025, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Feb 13, 2025, 8:00 AM EST - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Jan 28, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Jan 22, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 21, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Dec 23, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Dec 17, 2024, 8:50 AM EST - 1 year ago

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Dec 9, 2024, 3:42 PM EST - 1 year ago

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2024, 8:45 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Dec 4, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Nov 12, 2024, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Nov 6, 2024, 1:20 PM EST - 1 year ago

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Nov 6, 2024, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Oct 17, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Oct 9, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Oct 4, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Sep 30, 2024, 9:00 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sep 25, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Sep 4, 2024, 9:15 AM EDT - 1 year ago

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

Aug 19, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Aug 14, 2024, 8:35 AM EDT - 1 year ago

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Jul 24, 2024, 3:00 PM EDT - 1 year ago

Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Jul 24, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study

May 28, 2024, 8:00 AM EDT - 1 year ago

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

May 20, 2024, 9:15 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

May 14, 2024, 4:15 PM EDT - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

May 6, 2024, 7:00 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

Mar 19, 2024, 7:30 AM EDT - 2 years ago

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

nerowinger Feb. 3 at 8:30 PM

$PURR i dont no whats better holding purr or hype coin??

0 · Reply

nerowinger Feb. 3 at 7:23 PM

$PURR added

0 · Reply

Concreteslinger Feb. 3 at 6:58 PM

$PURR when options?!?

0 · Reply

insanitywolftrading Feb. 3 at 2:34 PM

$PURR son of a bitch

0 · Reply

insanitywolftrading Feb. 3 at 2:02 PM

$PURR need this shit to double so daddy can get a vasectomy!!!

0 · Reply

insanitywolftrading Feb. 3 at 12:48 PM

$PURR $HYPE.X look at this moist fellow who thinks now is a good time to bet against HYPEmentum season. It’s going up little fella, I just thought it would go up more. It’s getting there

0 · Reply

insanitywolftrading Feb. 3 at 12:36 PM

$HYPE.X huh I thought $PURR would be up given this huge move

1 · Reply

insanitywolftrading Feb. 3 at 4:01 AM

$HYPE.X $PURR is gonna go nuts tomorrow

0 · Reply

cheating_stock_investor Feb. 3 at 2:49 AM

$HYPD $HYPE.X $PURR $HYPE.X should break ath the first q of this year. Until x payments gets their payment platform up this should replace $DOGE.X in the top 10

0 · Reply

insanitywolftrading Feb. 3 at 1:58 AM

$HYPD $HYPE.X $PURR these are all gonna rip tomorrow we caught a big move

0 · Reply

Jstockdaddy Feb. 3 at 1:51 AM

$HYPD has 27% short interest, low float, high insider ownership. This thing is going to explode 💣💣 $HYPE.X $PURR coin trending

0 · Reply

Jestofunk Feb. 3 at 12:47 AM

$HYPE.X $PURR if you don’t trade crypto sunshine you’re a dead beat. Keep holding $PURR paperhands!

0 · Reply

insanitywolftrading Feb. 3 at 12:44 AM

$HYPE.X There are advantages to owning HYPE, there are advantages to owning $PURR, not sure what the advantage is to owning neither one of them.

0 · Reply

insanitywolftrading Feb. 3 at 12:03 AM

$PURR you have no idea how far this can go….

0 · Reply

insanitywolftrading Feb. 3 at 12:01 AM

$HYPE.X $PURR hell yeah boys we can afford to lease a gf now, maybe even rent to own

0 · Reply

The_Assassin Feb. 2 at 11:55 PM

$INLF $FIEE $FATN $PURR final watchlist

0 · Reply

Godwins26 Feb. 2 at 11:50 PM

$INLF after hours run 😊🚀 $PURR $FIEE $CATX $AQST

0 · Reply

hyperliquidenjoyoor Feb. 2 at 11:12 PM

$PURR Soft kitty, warm kitty Little ball of fur Happy kitty, sleepy kitty Purr Purr Purr Speedy kitty, hoodie kitty Little ball of fur Running kitty, climbing kitty Purr Purr Purr

0 · Reply

insanitywolftrading Feb. 2 at 10:55 PM

$PURR

0 · Reply

TeenageMutantNinjaTrader Feb. 2 at 10:31 PM

$PURR what’s this crap? Lol

1 · Reply

insanitywolftrading Feb. 2 at 10:13 PM

$HYPE.X $PURR

0 · Reply

insanitywolftrading Feb. 2 at 9:56 PM

$PURR

0 · Reply

Market Cap	576.70M
Revenue (ttm)	1.00M
Net Income (ttm)	-16.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	10.93
Profit Margin	-1,601.00%
Debt to Equity Ratio	0.00

Volume	9,154,500
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	127.03M
Stochastic %K	75%
Beta	1.51
Analysts	Strong Sell
Price Target	$6.58